COVID-19 status quo: Emphasis on gastrointestinal and liver manifestations.

COVID-19 Epidemiology Gastrointestinal manifestations Immunosuppressed states Liver manifestations Status quo Virology

Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
14 Dec 2021
Historique:
received: 28 04 2021
revised: 23 07 2021
accepted: 25 11 2021
entrez: 20 1 2022
pubmed: 21 1 2022
medline: 22 1 2022
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) has caused one of the worst public health crises in modern history. Even though severe acute respiratory syndrome coronavirus 2 primarily affects the respiratory tract, gastrointestinal manifestations are well described in literature. This review will discuss the epidemiology, virology, manifestations, immunosuppressant states, and lessons learned from COVID-19. Observations: At the time of writing, COVID-19 had infected more than 111 million people and caused over 2.5 million deaths worldwide. Multiple medical comorbidities including obesity, pre-existing liver condition and the use of proton pump inhibitor have been described as risk factor for severe COVID-19. COVID-19 most frequently causes diarrhea (12.4%), nausea/vomiting (9%) and elevation in liver enzymes (15%-20%). The current data does not suggest that patients on immunomodulators have a significantly increased risk of mortality from COVID-19. The current guidelines from American Gastroenterological Association and American Association for the Study of Liver Diseases do not recommend pre-emptive changes in patients on immunosuppression if the patients have not been infected with COVID-19. Conclusions and relevance: The COVID-19 pandemic has prompted a change in structure and shape of gastroenterology departmental activities. Endoscopy should be performed only when necessary and with strict protective measures. Online consultations in the form of telehealth services and home drug deliveries have revolutionized the field.

Identifiants

pubmed: 35046624
doi: 10.3748/wjg.v27.i46.7969
pmc: PMC8678824
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

7969-7981

Informations de copyright

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: There is no conflict of interest.

Références

Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
J Med Virol. 2020 Jun;92(6):680-682
pubmed: 32124995
Gastroenterology. 2018 Aug;155(2):337-346.e10
pubmed: 29655835
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):1008-1016
pubmed: 32866433
J Med Virol. 2020 Oct;92(10):1818-1824
pubmed: 32437004
J Hepatol. 2020 Sep;73(3):566-574
pubmed: 32298767
Am J Med Sci. 2020 Jul;360(1):5-34
pubmed: 32620220
World J Clin Cases. 2020 Oct 6;8(19):4303-4310
pubmed: 33083389
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Lancet Infect Dis. 2020 Jul;20(7):774-775
pubmed: 32243815
Cell Death Differ. 2021 Feb;28(2):626-639
pubmed: 33479399
JAMA. 2020 Nov 10;324(18):1899-1901
pubmed: 32970139
J Clin Exp Hepatol. 2020 May-Jun;10(3):263-265
pubmed: 32405183
Emerg Infect Dis. 2019 Jan;25(1):1-4
pubmed: 30560777
Gut. 2022 Jan;71(1):226-229
pubmed: 34083386
J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235486
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Mil Med Res. 2020 Jun 7;7(1):28
pubmed: 32507110
J Zhejiang Univ Sci B. 2020 Sept.;21(9):749-751
pubmed: 32893532
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Cancer J. 2014 Mar-Apr;20(2):119-22
pubmed: 24667956
J Hepatol. 2021 Mar;74(3):567-577
pubmed: 33035628
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
Am J Gastroenterol. 2020 Jun;115(6):916-923
pubmed: 32301761
J Clin Pharm Ther. 2008 Jun;33(3):215-7
pubmed: 18452407
Hepatology. 2020 Jul;72(1):287-304
pubmed: 32298473
JAMA. 2021 Mar 23;325(12):1185-1195
pubmed: 33635310
Gut. 2020 Jun;69(6):1141-1143
pubmed: 32102928
ACG Case Rep J. 2020 Jun 11;7(6):e00392
pubmed: 32637437
Cureus. 2020 Nov 30;12(11):e11786
pubmed: 33409033
PLoS One. 2020 Dec 10;15(12):e0243700
pubmed: 33301529
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
Sci Rep. 2020 Dec 17;10(1):22139
pubmed: 33335141
Nat Med. 2018 Jan;24(1):73-83
pubmed: 29227475
Gut. 2020 Jun;69(6):997-1001
pubmed: 32241899
Signal Transduct Target Ther. 2020 Jun 19;5(1):100
pubmed: 32561706
Dig Dis. 2020;38(5):373-379
pubmed: 32599601
Ann Surg. 2020 Aug;272(2):e61-e62
pubmed: 32675498
World J Gastroenterol. 2020 May 21;26(19):2323-2332
pubmed: 32476796
J Clin Virol. 2020 Jul;128:104386
pubmed: 32388469
J Gastroenterol Hepatol. 2020 May;35(5):744-748
pubmed: 32215956
Hepatology. 2019 Jan;69(1):294-313
pubmed: 30076625
Nat Struct Mol Biol. 2020 Aug;27(8):763-767
pubmed: 32647346
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
Nat Med. 2021 Jan;27(1):9
pubmed: 33442004
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Gastroenterology. 2020 Jul;159(1):350-357
pubmed: 32283100
Clin Imaging. 2021 May;73:86-95
pubmed: 33341452
Therapie. 2021 Jul-Aug;76(4):277-283
pubmed: 34049688
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):97-99
pubmed: 32075364
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Aliment Pharmacol Ther. 2020 May;51(9):843-851
pubmed: 32222988
Curr Drug Metab. 2018;19(2):142-154
pubmed: 29219052
Turk J Med Sci. 2020 Apr 17;50(SI-1):563-570
pubmed: 32299206
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566
pubmed: 32283325
Mayo Clin Proc. 2020 Aug;95(8):1632-1648
pubmed: 32753138
Int J Antimicrob Agents. 2020 Aug;56(2):106024
pubmed: 32450197
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
Front Med (Lausanne). 2021 Jan 27;7:606429
pubmed: 33585508
PLoS Pathog. 2020 Oct 30;16(10):e1009037
pubmed: 33125439
Science. 2020 Jul 3;369(6499):50-54
pubmed: 32358202
Gastroenterology. 2020 Jul;159(1):320-334.e27
pubmed: 32407808
J Intern Med. 2021 Jan;289(1):121-124
pubmed: 32608546
Gastroenterology. 2020 Aug;159(2):772-774.e13
pubmed: 32376410
Wellcome Open Res. 2020 May 13;5:94
pubmed: 32587902
Am J Gastroenterol. 2013 Feb;108(2):240-8
pubmed: 23295276
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765
pubmed: 32555134
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508

Auteurs

Abhishek Bhurwal (A)

Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.

Carlos D Minacapelli (CD)

Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.

Evan Orosz (E)

Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.

Kapil Gupta (K)

Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.

Christopher Tait (C)

Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.

Ishita Dalal (I)

Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.

Clark Zhang (C)

Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.

Eric Zhao (E)

Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.

Vinod K Rustgi (VK)

Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH